NEULANDLAB2023-04-012023-06-30 NEULANDLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2023-06-30 NEULANDLAB2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524558 NEULANDLAB NOTLISTED Neuland Laboratories Limited Equity 2023-04-01 2024-03-31 2023-08-03 2023-07-10 INR Lakhs First quarter 12:15:00 14:45:00 2023-08-03 2023-08-03 Not applicable Single segment Manufacturing of Active Pharmaceutical Ingredients 2023-04-01 2023-06-30 Unaudited Consolidated 3629939000.00 20389000.00 3650328000.00 1648649000.00 0.00 -192355000.00 598885000.00 22138000.00 135858000.00 605558000.00 2818733000.00 831595000.00 0.00 831595000.00 209475000.00 3330000.00 212805000.00 0.00 618790000.00 0.00 0.00 0.00 0.00 618790000.00 -143000.00 618647000.00 0.00 0.00 0.00 0.00 129005000.00 10 48.23 48.23 0.00 0.00 48.23 48.23 1. The financial results for the quarter ended 30 June 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 3 August 2023. 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA (b) Neuland Laboratories KK., Japan. 4. The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . 5. The EPS for quarters has not been annualised. 6. The figures for the quarter ended March 31, 2023 is the balancing figures between the audited figures in respect of the full financial year and the published unaudited figures upto nine months of the relevant financial year. Manufacturing expenses 379754000.00 Other expenses 225804000.00 Net (loss)/gain on equity securities 350000.00 350000.00 0.00 Exchange differences in translating the financial statements of foreign operations -493000.00 -493000.00 0.00